---
title: "Introducing escalation"
subtitle: "An R package to unify the interface of dose-escalation models in R."
summary: "An R package to unify the interface of dose-escalation models in R. A modular approach that is scalable and extensible."
authors: 
  - admin
categories:
- Code
tags:
  - escalation
  - R
projects: []
date: '2020-02-13'
lastmod: '2020-02-13T20:02:56Z'
draft: false
featured: yes
image:
  caption: 'Photo by [Martin Adams on Unsplash](https://unsplash.com/photos/sson9rOoy5Y)'
  focal_point: ''
  preview_only: no
bibliography: library.bib
---



<div id="escalation" class="section level1">
<h1>escalation <img src="https://github.com/brockk/escalation/raw/master/man/figures/logo.png" align="right" height=140/></h1>
<p><a href="https://github.com/brockk/escalation"><strong>escalation</strong></a> is a new R package that takes existing dose-finding models and gives them a common interface.
To use the language of <a href="https://www.tidyverse.org/">tidyverse</a> R, <strong>escalation</strong> provides a grammar for dose-finding by breaking the dose-finding process into chunks.
What model should I use?
How should I select dose during the trial?
How will I know when to stop?
Which restrictions should I place on escalation and de-escalation?
You can create the dose-finding design you want in <strong>escalation</strong> by combining elements that perform all of these tasks.
This might all sound a little obtuse.
Some examples will make it clear.</p>
<div id="examples" class="section level2">
<h2>Examples</h2>
<div id="crm" class="section level4">
<h4>CRM</h4>
<p><span class="citation">O’Quigley, Pepe, and Fisher (1990)</span> introduced the classic continual reassessment method (CRM) and it has been implemented in many software packages since.
One of the most popular R implementations is the <a href="https://CRAN.R-project.org/package=dfcrm">dfcrm</a> package by <span class="citation">Cheung (2013)</span>.
Let’s fit a model using dfcrm.</p>
<p>The very least information we need to provide is a dose-toxicity skeleton, and our target toxicity level:</p>
<pre class="r"><code>skeleton &lt;- c(0.05, 0.1, 0.25, 0.4, 0.6)
target &lt;- 0.25</code></pre>
<p>We use these to create a model-fitting object:</p>
<pre class="r"><code>library(escalation)
model &lt;- get_dfcrm(skeleton = skeleton, target = target)</code></pre>
<p>The model can then be fit to outcomes.
The escalation package uses the outcome syntax introduced for phase I trials in <span class="citation">Brock (2019)</span> and for seamless phase I/II trials in <span class="citation">Brock et al. (2017)</span>.
Let’s assume we have treated 3 patients at dose-level 2 and none of them experienced toxicity.
We represent this using the outcome string <code>2NNN</code>.
Fitting the model to the set of outcomes invokes the dose-selection algorithm:</p>
<pre class="r"><code>fit &lt;- model %&gt;% fit(&#39;2NNN&#39;)</code></pre>
<p>and the fit object will tell you the dose recommended by the CRM model to be administered next:</p>
<pre class="r"><code>fit %&gt;% recommended_dose()</code></pre>
<pre><code>## [1] 4</code></pre>
<p>The model advocates skipping straight from dose 2 to dose 4.
Clinicians are unlikely to feel comfortable with this.
We can respecify the model to expressly not skip doses in escalation:</p>
<pre class="r"><code>model &lt;- get_dfcrm(skeleton = skeleton, target = target) %&gt;% 
  dont_skip_doses(when_escalating = TRUE)</code></pre>
<p>We have taken the original dfcrm model and added an extra module to prevent skipping doses in escalation.
Refitting the new model to the same outcomes gives:</p>
<pre class="r"><code>fit &lt;- model %&gt;% fit(&#39;2NNN&#39;)
fit %&gt;% recommended_dose()</code></pre>
<pre><code>## [1] 3</code></pre>
<p>We see that the ensemble now decides to select dose 3.
We can ask the trial design whether it wants to keep recruting patients:</p>
<pre class="r"><code>fit %&gt;% continue()</code></pre>
<pre><code>## [1] TRUE</code></pre>
<p>Naturally it wants to continue because <code>dfcrm</code> does not implement any stopping rules.
However, we can easily add some.
Let us say that we want to stop once the model has evaluated 18 patients, or at least 9 at the dose being recommended, whichever occurs first.
We specify this model by adding more behaviours:</p>
<pre class="r"><code>model &lt;- get_dfcrm(skeleton = skeleton, target = target) %&gt;% 
  dont_skip_doses(when_escalating = TRUE) %&gt;% 
  stop_at_n(n = 18) %&gt;% 
  stop_when_n_at_dose(dose = &#39;recommended&#39;, n = 9)</code></pre>
<p>Let’s fit this model to some more patients to see how this trial plays out:</p>
<pre class="r"><code>fit &lt;- model %&gt;% fit(&#39;2NNN 3TTN&#39;)
fit %&gt;% recommended_dose()</code></pre>
<pre><code>## [1] 2</code></pre>
<pre class="r"><code>fit %&gt;% continue()</code></pre>
<pre><code>## [1] TRUE</code></pre>
<p>After seeing two-in-three patients in the second cohort experience toxicity at dose 3, the design understandably wants to de-escalate.
Let’s do that:</p>
<pre class="r"><code>fit &lt;- model %&gt;% fit(&#39;2NNN 3TTN 2TNN&#39;)
fit %&gt;% recommended_dose()</code></pre>
<pre><code>## [1] 2</code></pre>
<pre class="r"><code>fit %&gt;% continue()</code></pre>
<pre><code>## [1] TRUE</code></pre>
<p>The third cohort yielded one-in-three tox at dose 2.
The design wants to continue at dose 2 so let’s do that:</p>
<pre class="r"><code>fit &lt;- model %&gt;% fit(&#39;2NNN 3TTN 2TNN 2NNT&#39;)
fit %&gt;% recommended_dose()</code></pre>
<pre><code>## [1] 2</code></pre>
<pre class="r"><code>fit %&gt;% continue()</code></pre>
<pre><code>## [1] FALSE</code></pre>
<p>Notice that the call to continue() now returns FALSE.
The design wants to stop now and recommend dose 2.
It does this because it has seen 9 patients at the recommended dose.
We can see the number of patients treated at each of the five doses under investigation:</p>
<pre class="r"><code>fit %&gt;% n_at_dose()</code></pre>
<pre><code>## [1] 0 9 3 0 0</code></pre>
<p>Our stopping criteria have been met.
We can verify that dose 2 is indeed the dose with posterior expected toxicity rate closest to our target of 25%:</p>
<pre class="r"><code>fit %&gt;% mean_prob_tox()</code></pre>
<pre><code>## [1] 0.1845713 0.2728713 0.4575229 0.5964102 0.7496662</code></pre>
</div>
<div id="boin" class="section level4">
<h4>BOIN</h4>
<p><code>escalate</code> also implements the BOIN dose-finding design by <span class="citation">Liu and Yuan (2015)</span> via the <a href="https://CRAN.R-project.org/package=BOIN"><code>BOIN</code></a> R-package <span class="citation">(Yuan and Liu 2018)</span>.</p>
<p>In contrast to CRM, BOIN does not require a dose-toxicity skeleton.
In its simplest case, it requires merely the number of doses under investigation and our target toxicity level:</p>
<pre class="r"><code>target &lt;- 0.25
model &lt;- get_boin(num_doses = 5, target = target)</code></pre>
<p>As before, we can fit the model to some observed outcomes:</p>
<pre class="r"><code>fit &lt;- model %&gt;% fit(&#39;2NNN&#39;)
fit %&gt;% recommended_dose()</code></pre>
<pre><code>## [1] 3</code></pre>
<pre class="r"><code>fit %&gt;% continue()</code></pre>
<pre><code>## [1] TRUE</code></pre>
<p>The BOIN dose selector natively implements stopping rules, as described by Liu &amp; Yuan.
For instance, if the bottom dose is too toxic, the design will advise the trial halts:</p>
<pre class="r"><code>fit &lt;- model %&gt;% fit(&#39;2NTN 1TTT&#39;)
fit %&gt;% recommended_dose()</code></pre>
<pre><code>## [1] NA</code></pre>
<pre class="r"><code>fit %&gt;% continue()</code></pre>
<pre><code>## [1] FALSE</code></pre>
<p>Nevertheless, as with the CRM examples above, our BOIN selector can be adorned with various behaviours to tailor stopping and skipping.
In fact, we can add the exact same behaviours as before because all <code>escalation</code> objects support exactly the same interface.
This makes the package completely modular.
We are building the design we want from pieces of Lego:</p>
<pre class="r"><code>model &lt;- get_boin(num_doses = 5, target = target) %&gt;% 
  dont_skip_doses(when_escalating = TRUE) %&gt;% 
  stop_at_n(n = 18) %&gt;% 
  stop_when_n_at_dose(dose = &#39;recommended&#39;, n = 9)

fit &lt;- model %&gt;% fit(&#39;2NNN 3TTN 2TNN 2NNT&#39;)
fit %&gt;% recommended_dose()</code></pre>
<pre><code>## [1] 2</code></pre>
<pre class="r"><code>fit %&gt;% continue()</code></pre>
<pre><code>## [1] FALSE</code></pre>
<pre class="r"><code>fit %&gt;% mean_prob_tox()</code></pre>
<pre><code>## [1]   NA 0.23 0.66   NA   NA</code></pre>
<p>Notice that the posterior toxicity estimate is similar to the CRM model at dose 2, but ultimately different because the two approaches use different model forms.
BOIN does not estimate the tox rate at doses that have not been administered.</p>
</div>
<div id="initial-escalation-plans" class="section level4">
<h4>Initial escalation plans</h4>
<p>Another dose-selection mechanism supported by escalation is the concept of an <em>initial escalation plan</em>.
These can be used at the start of a trial to show how escalation should proceed initially.
As soon as the realised outcomes diverge from the prespecified path, or the path reaches the end, a secondary model takes over.</p>
<p>For instance, let us assume we would like to treat one patient per dose so long as no toxicity is seen, in order to facilitate fast escalation.
When toxicity is seen, or dose five is reached, we would like to hand control to a CRM model.
We can write:</p>
<pre class="r"><code>model &lt;- follow_path(&#39;1N 2N 3N 4N 5N&#39;) %&gt;% 
  get_dfcrm(skeleton = skeleton, target = target)</code></pre>
<p>So long as the idealised path is realised, it continues:</p>
<pre class="r"><code>model %&gt;% 
  fit(&#39;1N&#39;) %&gt;% 
  recommended_dose()</code></pre>
<pre><code>## [1] 2</code></pre>
<pre class="r"><code>model %&gt;% 
  fit(&#39;1N 2N&#39;) %&gt;% 
  recommended_dose()</code></pre>
<pre><code>## [1] 3</code></pre>
<p>But if the path is deviated from, the secondary model takes over:</p>
<pre class="r"><code>model %&gt;% 
  fit(&#39;1N 2N 3T&#39;) %&gt;% 
  recommended_dose()</code></pre>
<pre><code>## [1] 2</code></pre>
<p>Also, when the initial path is completed, the secondary model continues:</p>
<pre class="r"><code>model %&gt;% 
  fit(&#39;1N 2N 3N 4N 5N&#39;) %&gt;% 
  recommended_dose()</code></pre>
<pre><code>## [1] 5</code></pre>
</div>
</div>
<div id="summary" class="section level2">
<h2>Summary</h2>
<p>The <strong>escalation</strong> package takes dose-finding methods that other authors have provided and gives them a consistent interface.
This makes it simple to add any behaviour to any method, creating a modular Lego-like approach to creating dose-finding designs.
For instance, we can take any dose-selection model and tweak the way it selects the next dose, the way it escalates, de-escalates and stops.
I hope eventually that <strong>escalation</strong> makes it easy to specify, assess and compare all dose-escalation designs.</p>
</div>
<div id="roadmap" class="section level2">
<h2>Roadmap</h2>
<p>Version 0.0.1 has been submitted to CRAN (but as of 2020-02-17, not yet accepted) with the following base dose-finding approaches:</p>
<ul>
<li>the CRM model from the <a href="https://CRAN.R-project.org/package=dfcrm"><code>dfcrm</code></a> package</li>
<li>the BOIN model from the <a href="https://CRAN.R-project.org/package=BOIN"><code>BOIN</code></a> package</li>
<li>the perennial 3+3 model without dose de-escalation</li>
</ul>
<p>and the following optional embellishments:</p>
<ul>
<li>don’t skip doses in escalation and/or de-escalation</li>
<li>stop when dose(s) are too toxic</li>
<li>stop when <span class="math inline">\(n\)</span> patients have been treated in total</li>
<li>stop when <span class="math inline">\(n\)</span> patients have been treated at a particular dose</li>
<li>use an initial fixed dose-escalation plan</li>
<li>demand at least <span class="math inline">\(n\)</span> patients have been treated at a particular dose before stopping is permitted.</li>
</ul>
<p>In future versions, the following base dose-finding approaches will probably be added:</p>
<ul>
<li>the EWOC model from the <a href="https://CRAN.R-project.org/package=EWOC"><code>EWOC</code></a> package</li>
<li>the CRM and EffTox models from the <a href="https://CRAN.R-project.org/package=trialr"><code>trialr</code></a> package</li>
<li>the CRM model from the <a href="https://CRAN.R-project.org/package=bcrm"><code>bcrm</code></a> package</li>
<li>the CRM model from the <a href="https://CRAN.R-project.org/package=crmPack"><code>crmPack</code></a> package</li>
</ul>
<p>Before I plough into the MCMC methods (trialr, bcrm, crmPack), I want to understand the implications of adding other software to the dependency chain to what at the moment is a very lightweight package.</p>
<p>In addition to those, I plan to add further behaviours that allow:</p>
<ul>
<li>stopping under the conditions investigated by <span class="citation">Zohar and Chevret (2001)</span>;</li>
<li>selecting dose by the CIBP criterion of <span class="citation">Mozgunov and Jaki (2020)</span>.</li>
</ul>
<p>Independent to the work described above, I will add functions that run simulations and calculate dose pathways.</p>
</div>
<div id="how-escalation-came-about" class="section level2">
<h2>How escalation came about</h2>
<p>It had bothered me for several years that it always seemed so difficult to tweak behaviour of dose-finging designs to allow flexible stopping (etc).
In my trials unit, we frequently started with the dfcrm code and then added custom embellishments to achieve the design and behaviour we wanted in each particular trial.
Running simulations or calculating future dose pathways was never as simple as it should have been.
The approach we used of tweaking dfcrm implicitly assumed we needed a more complex dose-fitting function.
And then one night at about 4am when I was neither asleep nor awake, I realised that we needed to daisy-chain the dose-selecting classes together to augment behaviour.
We did not need a more complex dose-fitting function, we needed a flexible way of combining simple functions.
Having used dplyr and tidyverse packages for years now, the <code>%&gt;%</code> operator seemed the natural solution.</p>
</div>
<div id="installation" class="section level2">
<h2>Installation</h2>
<pre class="r"><code># Once it hits CRAN, install the latest official version with:
install.packages(&quot;escalation&quot;)

# Alternatively, install the latest code at any time from GitHub:
devtools::install_github(&quot;brockk/escalation&quot;)</code></pre>
</div>
<div id="resources" class="section level2">
<h2>Resources</h2>
<p><img src="https://github.com/brockk/escalation/raw/master/man/figures/logo.png" align="right" height=140/></p>
<!-- * [CRAN package page](https://cran.r-project.org/package=escalation) -->
<ul>
<li><a href="https://github.com/brockk/escalation">GitHub repo</a></li>
<li><a href="https://brockk.github.io/escalation/">Documentation</a></li>
</ul>
</div>
<div id="references" class="section level2 unnumbered">
<h2>References</h2>
<div id="refs" class="references">
<div id="ref-Brock2019">
<p>Brock, Kristian. 2019. “trialr: Bayesian Clinical Trial Designs in R and Stan.” <em>arXiv E-Prints</em>, June, arXiv:1907.00161.</p>
</div>
<div id="ref-Brock2017a">
<p>Brock, Kristian, Lucinda Billingham, Mhairi Copland, Shamyla Siddique, Mirjana Sirovica, and Christina Yap. 2017. “Implementing the EffTox Dose-Finding Design in the Matchpoint Trial.” <em>BMC Medical Research Methodology</em> 17 (1): 112. <a href="https://doi.org/10.1186/s12874-017-0381-x">https://doi.org/10.1186/s12874-017-0381-x</a>.</p>
</div>
<div id="ref-dfcrm">
<p>Cheung, Ken. 2013. <em>Dfcrm: Dose-Finding by the Continual Reassessment Method</em>. <a href="https://CRAN.R-project.org/package=dfcrm">https://CRAN.R-project.org/package=dfcrm</a>.</p>
</div>
<div id="ref-liu_bayesian_2015">
<p>Liu, Suyu, and Ying Yuan. 2015. “Bayesian Optimal Interval Designs for Phase I Clinical Trials.” <em>Journal of the Royal Statistical Society: Series C (Applied Statistics)</em> 64 (3): 507–23. <a href="https://doi.org/10.1111/rssc.12089">https://doi.org/10.1111/rssc.12089</a>.</p>
</div>
<div id="ref-mozgunovImprovingSafetyContinual">
<p>Mozgunov, Pavel, and Thomas Jaki. 2020. “Improving Safety of the Continual Reassessment Method via a Modified Allocation Rule.” <em>Statistics in Medicine</em>, 1–17. <a href="https://doi.org/10.1002/sim.8450">https://doi.org/10.1002/sim.8450</a>.</p>
</div>
<div id="ref-OQuigley1990">
<p>O’Quigley, J, M Pepe, and L Fisher. 1990. “Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer.” <em>Biometrics</em> 46 (1): 33–48. <a href="https://doi.org/10.2307/2531628">https://doi.org/10.2307/2531628</a>.</p>
</div>
<div id="ref-BOIN">
<p>Yuan, Ying, and Suyu Liu. 2018. <em>BOIN: Bayesian Optimal Interval (Boin) Design for Single-Agent and Drug- Combination Phase I Clinical Trials</em>. <a href="https://CRAN.R-project.org/package=BOIN">https://CRAN.R-project.org/package=BOIN</a>.</p>
</div>
<div id="ref-zohar_continual_2001">
<p>Zohar, Sarah, and Sylvie Chevret. 2001. “The Continual Reassessment Method: Comparison of Bayesian Stopping Rules for Dose-Ranging Studies.” <em>Statistics in Medicine</em> 20 (19): 2827–43. <a href="https://doi.org/10.1002/sim.920">https://doi.org/10.1002/sim.920</a>.</p>
</div>
</div>
</div>
</div>
